Multicenter clinical study of immune-cell therapy in patients with malignant tumors.

Multicenter clinical study of i.v. injected 2DG-Killer T cell therapy in patients with malignant tumors.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTc030220555

Enrollment

6000

Registered

2022-01-04

Start date

2015-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant tumor

Interventions

blood collection for cell culture and tests.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Diagnostic imaging or Pathological diagnosis of malignant tumor. (2)Informed consent has been obtained.

Exclusion criteria

Exclusion criteria: (1)HIV Ab positive. (2)T cell- or NK cell-originated leukemia and/or lymphoma.(LAK therapy) (3)Patients who have previously treated allogenic transplantation. (4)Responsible doctors judged the patient inappropriate for the clinical study.

Design outcomes

Primary

Measure	Time frame
Safety, Immunological response	—

Secondary

Measure	Time frame
Efficacy	—

Countries

Japan

Contacts

Public ContactTakashi Kamigaki

Koshikai, Non-profit Medical Corporation

citeg@j-immunother.com+81-3-5244-5751

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026